MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Sarepta Therapeutics Inc

Abrir

SetorSaúde

60.91 0.35

Visão Geral

Variação de preço das ações

24h

Atual

Mín

59.75

Máximo

61.86

Indicadores-chave

By Trading Economics

Rendimento

125M

159M

Vendas

191M

658M

P/E

Médio do Setor

23.603

57.333

EPS

1.9

Margem de lucro

24.156

Funcionários

1,372

EBITDA

138M

187M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+140.04% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-5.3B

5.4B

Abertura anterior

60.56

Fecho anterior

60.91

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bullish Evidence

Sarepta Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

31 de mar. de 2025, 14:19 UTC

Grandes Movimentos do Mercado

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

20 de jun. de 2024, 23:05 UTC

Grandes Movimentos do Mercado

Sarepta Shares Soar 37% Following Expanded Approval for Elevidys

21 de jun. de 2024, 08:58 UTC

Principais Notícias

These Stocks Are Moving the Most Today: Microsoft, Nvidia, Trump Media, Sarepta, CarMax, and More -- Barrons.com

Comparação entre Pares

Variação de preço

Sarepta Therapeutics Inc Previsão

Preço-alvo

By TipRanks

140.04% parte superior

Previsão para 12 meses

Média 148.25 USD  140.04%

Máximo 209 USD

Mínimo 70 USD

Com base em 22 analistas de Wall Street que oferecem metas de preço de 12 meses para Sarepta Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

22 ratings

18

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

59.31 / 62.78Suporte e Resistência

Curto Prazo

Very Strong Bullish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.